A Study to Evaluate the Efficacy and Safety of Dapirolizumab Pegol in Study Participants With Moderately to Severely Active Systemic Lupus Erythematosus
Clinical trial NCT06617325 · RECRUITING
Trial details
- NCT number
- NCT06617325
- Sponsor
- UCB Biopharma SRL
- Status
- RECRUITING
- Phase
- Phase 3
- Study type
- INTERVENTIONAL
- Start date
- 2024-11-21
- Primary completion
- 2028-05-31
- Enrollment
- 450
Track trials programmatically
Sponsors, conditions and status changes through the Atlas API.